- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2018
- Public Summary Document (PSD) July 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2018 PBAC Meeting - Word
Blinatumomab – July 2018
Blinatumomab: Powder for I.V. infusion 38.5 micrograms; Blincyto®
Last updated
9 November 2018